While the clinical impact of mutations in the ABL1 gene on response to therapy in chronic phase chronic myeloid leukemia (CP-CML) is well established, less is known about how other mutations affect prognosis. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.